We are live on ! Find out more
AUPH icon

Aurinia Pharmaceuticals
AUPH

115 hedge funds and large institutions have $992M invested in Aurinia Pharmaceuticals in 2019 Q4 according to their latest regulatory filings, with 52 funds opening new positions, 28 increasing their positions, 19 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

629% more capital invested

Capital invested by funds: $136M → $992M (+$856M)

550% more first-time investments, than exits

New positions opened: 52 | Existing positions closed: 8

127% more call options, than puts

Call options by funds: $89.1M | Put options by funds: $39.3M

60% more funds holding

Funds holding: 72 → 115 (+43)

47% more repeat investments, than reductions

Existing positions increased: 28 | Existing positions reduced: 19

17.96% more ownership

Funds ownership: 27.74% → 45.7% (+18%)

Holders
115
Holders Change
+43
Holders Change %
+59.72%
% of All Funds
2.27%
Holding in Top 10
6
Holding in Top 10 Change
+6
Holding in Top 10 Change %
% of All Funds
0.12%
New
52
Increased
28
Reduced
19
Closed
8
Calls
$89.1M
Puts
$39.3M
Net Calls
+$49.8M
Net Calls Change
+$49.3M

Top Buyers

Rank Fund Capital Flow
1
Fidelity Investments
Fidelity Investments
Massachusetts
+$63.6M
2
CCM
Consonance Capital Management
New York
+$37.4M
3
HM
HealthCor Management
New York
+$36.7M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
+$32.9M
5
BBA
Baker Bros. Advisors
New York
+$15.7M

Top Sellers

Rank Fund Capital Flow
1
PC
Polar Capital
United Kingdom
-$17.7M
2
O
OrbiMed
New York
-$10.9M
3
Goldman Sachs
Goldman Sachs
New York
-$9.5M
4
Ameriprise
Ameriprise
Minnesota
-$1.96M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
-$1.79M
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$163M +$63.6M +6,904,314 +613%
CCM
2
Consonance Capital Management
New York
$134M +$37.4M +4,064,402 +159%
NMC
3
NEA Management Company
Maryland
$105M – – –
HM
4
HealthCor Management
New York
$97.7M +$36.7M +3,987,960 +479%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$72.8M +$32.9M +3,573,880 +16,429%
O
6
OrbiMed
New York
$47.5M -$10.9M -1,185,555 -34%
Millennium Management
7
Millennium Management
New York
$39.4M +$12.8M +1,386,635 +248%
BBA
8
Baker Bros. Advisors
New York
$34.5M +$15.7M +1,701,929 New
Franklin Resources
9
Franklin Resources
California
$26.9M -$732K -79,500 -6%
ACP
10
Acuta Capital Partners
California
$21.4M +$1.91M +207,500 +24%
Citadel Advisors
11
Citadel Advisors
Florida
$19M +$8.13M +882,480 +1,604%
BlackRock
12
BlackRock
New York
$17.6M -$385K -41,849 -5%
Susquehanna International Group
13
Susquehanna International Group
Pennsylvania
$17.5M +$2.02M +219,334 +34%
PA
14
Perceptive Advisors
New York
$14.5M +$6.6M +716,666 New
Goldman Sachs
15
Goldman Sachs
New York
$12.6M -$9.5M -1,030,898 -62%
GTC
16
Ghost Tree Capital
New York
$12.2M +$5.53M +600,000 New
Renaissance Technologies
17
Renaissance Technologies
New York
$11.7M +$5.23M +567,789 +5,284%
IC
18
Ikarian Capital
Texas
$9.75M +$4.43M +481,104 New
BC
19
Broadfin Capital
New York
$8.1M +$3.68M +400,000 New
CLCM
20
Crawford Lake Capital Management
New Jersey
$7.25M +$3.3M +358,082 New
Hudson Bay Capital Management
21
Hudson Bay Capital Management
Connecticut
$7.09M -$461K -50,000 -13%
AI
22
Atom Investors
Texas
$6.96M +$3.17M +343,651 New
SSA
23
Schonfeld Strategic Advisors
New York
$6.33M +$2.88M +312,268 New
Victory Capital Management
24
Victory Capital Management
Texas
$5.52M – – –
PVI
25
Pura Vida Investments
New York
$5.41M +$2.46M +267,050 New
1
2 3 4 5

AUPH Hedge Fund Activity: Q4 2019 in Review

115 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q4 2019, worth a combined $992M — up 629% from $136M a quarter earlier.

Buyers outnumbered sellers: 52 funds opened new AUPH positions and 8 closed out — a net gain of 44 holders — while 28 added to existing stakes and 19 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $63.6M. The largest seller was Polar Capital, exiting entirely with an estimated $17.7M sold.

  • 115 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q4 2019, up from 72 in Q3 2019.
  • Funds reported $992M of Aurinia Pharmaceuticals stock for Q4 2019, up 629% quarter-over-quarter.
  • 52 funds opened new Aurinia Pharmaceuticals positions in Q4 2019 and 8 closed out, a net change of +44 holders.
  • The largest Aurinia Pharmaceuticals buyer in Q4 2019 was Fidelity Investments, an estimated $63.6M added.
  • The largest Aurinia Pharmaceuticals seller in Q4 2019 was Polar Capital, an estimated $17.7M sold.

Based on aggregated 13F filings for Q4 2019.